Bioxytran, Inc. BIXT
Set alert
0.02 USD 0.00 +1.39%
At close · Oct 29
0.0205 Day range 0.0232
0.0201 52-week range 0.09
- YTD
- -72.98%
- 1 year
- -70.74%
- Open
- 0.0205
- Prev close
- 0.0202
- Mkt cap
- 2.35M
- Vol
- 43.50K
- Avg vol
- 100.02K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.0205
- High
- 0.0232
- Earnings
- Nov 2, 2023
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| Apr 19, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Mar 22, 2024 | Dec 1, 2023 | 0.00 | -0.01 | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Jul 31, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
News
- Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
- Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
- Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
- Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
- Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
- Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
- Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
- Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
- Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
Your note
Sign in to keep a note on BIXT — it syncs with the Stock Master app.